The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and conditions. In particular, combinations of scyllo-inositol and treatments for Alzheimer's disease such as aducanumab and/or combinations with essential fatty acids such as mixtures of linolenic acid/linoleic acid or vitamin D or vitamin D compounds such as calcifediol are disclosed as useful. The combinations may be in the form of separate dosage forms of each active ingredient or may be an oral dosage form having multiple active ingredients in a single capsule or tablet or oral solution. The invention also relates to a method of treating patients having mild cognitive impairment with MMSE criteria of between 22 to 26 with a pharmaceutically effective amount of scyllo-inositol to treat the disease and to slow down progression to Alzheimer's disease.
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the flavone apigenin to support cognitive health in a subject that takes the product or combination product. The invention relates to compositions comprising scyllo-inositol alone or in combination with other agents including but not limited to a flavone or other substance that upregulates or prevents the downregulation of aquaporin 4 channels. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system.
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
5.
SCYLLO-INOSITOL IN COMBINATION WITH IMMUNOTHERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and conditions. In particular, combinations of scyllo-inositol and treatments for Alzheimer's disease such as lecanemab are disclosed as useful.
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
6.
METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutritional Supplements; mineral food supplements, enzyme
dietary supplements, vitamin supplements; protein dietary
supplements, medical herbal extracts, medical nutritional
foods; dietary supplements; nutraceuticals for use as a
dietary supplement; vitamin preparations; pharmaceuticals;
pharmaceutical preparations; dietetic substances adapted for
medical use; none of the aforementioned goods related to
antiallergies and dermatics; none of the aforementioned
goods related to preparations for treating and/or preventing
sleep disturbances.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutritional supplements; mineral food supplements, enzyme
dietary supplements, vitamin supplements; protein dietary
supplements, medical herbal extracts, medical nutritional
foods; dietary supplements; nutraceuticals for use as a
dietary supplement; vitamin preparations; pharmaceuticals;
pharmaceutical preparations; dietetic substances adapted for
medical use.
11.
TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS FOR TREATMENT OF RENAL DISEASE
Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound. The methods of treatment disclosed herein also include co-administration of the tetrahydrocyclopenta[b]indole compound with a second composition
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary supplements, nutritional supplements, medical nutritional foods, pharmaceuticals and pharmaceutical preparations, all for the treatment and prevention of memory loss, treatment of cognitive impairment and neurological disorders; none of the aforementioned goods related to antiallergies and dermatics; none of the aforementioned goods related to preparations for treating and/or preventing sleep disturbances.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Nutritional supplements; mineral food supplements, enzyme dietary supplements, vitamin supplements; protein dietary supplements, medical herbal extracts, medical nutritional foods; dietary supplements; nutraceuticals for use as a dietary supplement; vitamin preparations; pharmaceuticals; pharmaceutical preparations; dietetic substances adapted for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutritional Supplements; mineral food supplements, enzyme dietary supplements, vitamin supplements; protein dietary supplements, medical herbal extracts, lyophilized, homogenized or freeze dried nutritional foods; dietary supplements; nutraceuticals for use as a dietary supplement; vitamin preparations; pharmaceuticals for treatment of cognitive impairment and neurological disorders; pharmaceutical preparations for treatment and prevention of memory loss, and neurological disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutritional Supplements; mineral food supplements, enzyme dietary supplements, vitamin supplements; protein dietary supplements, medical herbal extracts, medical nutritional foods, namely, lyophilized, homogenized, or freeze-dried food adapted for medical purposes; dietary supplements; nutraceuticals for use as a dietary supplement; vitamin preparations; pharmaceuticals for treatment of cognitive impairment and neurological disorders; pharmaceutical preparations for treatment and prevention of memory loss, and of neurological disorders; dietetic substances adapted for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary supplements, nutritional supplements, medical nutritional foods, pharmaceuticals and pharmaceutical preparations, all for the treatment and prevention of memory loss, treatment of cognitive impairment and neurological disorders; none of the aforementioned goods related to antiallergies and dermatics; none of the aforementioned goods related to preparations for treating and/or preventing sleep disturbances.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutritional Supplements; mineral food supplements, enzyme dietary supplements, vitamin supplements; protein dietary supplements, medical herbal extracts, medical nutritional foods; dietary supplements; nutraceuticals for use as a dietary supplement; vitamin preparations; pharmaceuticals; pharmaceutical preparations; dietetic substances adapted for medical use.
18.
Method of Controlling Progression of Hyperparathyroidism, And Compositions for Use Therein
A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals used in industry, science and photography; chemical substances for preserving foodstuffs; adhesives used in industry; biological preparations for use in biotechnology other than for medical use Pharmaceutical preparations and substances for the treatment of medical ailments and medical conditions, namely, cardiovascular and central nervous system disorders, malignant diseases and immunosuppression, musculoskeletal and joint diseases, ocular, gynecological and urinary tract disorders and infectious and non-infectious diseases; sanitary preparations for medical use; prescription pharmaceutical and biotechnological preparations for the treatment of medical ailments and medical conditions, namely, cardiovascular and central nervous system disorders, malignant diseases and immunosuppression musculoskeletal and joint diseases, ocular, gynecological and urinary tract disorders and infectious and non-infectious diseases; biological preparations for medical purposes, namely, for use in biotechnology for the treatment of cancer, infectious diseases, metabolic diseases and disorders; chemical preparations and reagents for use in biotechnology for medical and veterinary use, namely, renal diseases and disorders, cognitive and neurological disorders, vitamin D insufficiencies, cancer and infectious diseases; injectable solutions for medical purposes, namely, injectable pharmaceuticals for cardiovascular and central nervous system disorders, malignant diseases and immunosuppression, musculoskeletal and joint diseases, ocular, gynecological and urinary tract disorders; dietetic foods, namely, pasta, crackers, and bread, food supplements, infusions, drinks and beverages all adapted for medical use; all purpose disinfectants, oral disinfectants for medical and hygienic purposes, disinfectants for hygienic and sanitary purposes, disinfectants for medical instruments; syrups for pharmaceutical purposes, namely, cough syrups; vaccines; syringes containing pharmaceuticals for the treatment of cardiovascular and central nervous system disorders, malignant diseases and immunosuppression, musculoskeletal and joint diseases, ocular, gynecological and urinary tract disorders for medical use; pre-filled disposable syringes and hypodermic syringes containing pharmaceuticals for the treatment of cardiovascular and central nervous system disorders, malignant diseases and immunosuppression, musculoskeletal and joint diseases, ocular, gynecological and urinary tract disorders for medical use The provision of information on the subject of research and development, drug development and product evaluation all in the field of pharmaceuticals and biotechnology; scientific and industrial research relating to pharmaceuticals and biotechnology
21.
IMMEDIATE RELEASE DOSAGE FORMS, METHODS OF MAKING AND USING
Immediate release multiparticulate dosage forms, and methods of making and using the same, are disclosed. The dosage forms are directed to anti-cancer formulations suitable for people and animals.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.
Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.
Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound. The methods of treatment disclosed herein also include co-administration of the tetrahydrocyclopenta[b]indole compound with a second composition
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders.
The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
36.
Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating kidney disease; pharmaceutical preparations for the treatment of diseases and disorders of the parathyroid and renal disease; pharmaceuticals for the treatment of secondary hyperparathyroidism; preparations for the treatment of vitamin D deficiency
41.
Methods of treating vitamin D insufficiency in chronic kidney disease
Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.
3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
44.
Stabilized modified release vitamin D formulation and method of administering same
3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
45.
Stabilized modified release vitamin D formulation and method of administering same
3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
46.
Methods for controlled release oral dosage of a vitamin D compound
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information; Providing medical information; Providing medical information to health care providers in the form of reports in the field of chronic kidney disease
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
51.
Methods useful for vitamin D deficiency and related disorders
Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
A01N 45/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
52.
Method for controlled release oral dosage of a vitamin D compound
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
53.
Method of treating and preventing secondary hyperparathyroidism
There is provided a method of producing a mixed metal compound that includes at least Mg2+ and at least Fe3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 Å) comprising the steps of: (a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9.5 to 11, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0.03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product.
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
56.
Method for treating secondary hyperparathyroidism in CKD
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
57.
Methods useful for vitamin D deficiency and related disorders
Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
A01N 45/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
58.
Water-insoluble, iron-containing mixed metal, granular material
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; diagnostic preparations for veterinary purposes; pharmaceutical preparations for cats and dogs for use in oncology treatment.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of diseases and disorders of the parathyroid
and renal disease; pharmaceuticals for the treatment of
secondary hyperparathyroidism; preparations for the
treatment of vitamin D deficiency; nutritional supplements,
vitamin supplements.
61.
Methods for controlled release oral dosage of a vitamin D compound
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
62.
Stabilized modified release vitamin D formulation and method of administering same
3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
63.
STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations for the treatment of diseases and disorders of the parathyroid and renal disease; pharmaceutical preparations for the treatment of hyperparathyroidism; pharmaceuticals for the treatment of secondary hyperparathyroidism; pharmaceutical preparations for the treatment of vitamin D deficiency; nutritional supplements, vitamin supplements
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treating kidney disease; pharmaceutical preparations for the treatment of diseases and disorders of the parathyroid and renal disease; pharmaceuticals for the treatment of secondary hyperparathyroidism; preparations for the treatment of vitamin D deficiency.
3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.05 to 1 5 kg water per hour per kg of dry product, or (H) exposing the crude product to rapid drying at a water evaporation rate of 500 to 50000 kg water per hour per kg of dry product.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for the treatment of diseases and disorders of the parathyroid and renal disease; pharmaceuticals for the treatment of secondary hyperparathyroidism; preparations for the treatment of vitamin D deficiency; nutritional supplements, vitamin supplements.
68.
Methods and composition for measuring the amount of vitamin D derivatives
Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
69.
Method of treating and preventing secondary hyperparathyroidism
Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.05 to 1 5 kg water per hour per kg of dry product, or (H) exposing the crude product to rapid drying at a water evaporation rate of 500 to 50000 kg water per hour per kg of dry product.
Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.
This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
A01N 45/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
77.
Water-insoluble, iron-containing mixed metal, granular material
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A process for producing a compound of the formula:
including reacting of a compound of the formula:
3 is a protecting group, and the squiggly line represents a bond that results in the adjacent double bond being in either the E or Z configuration, is disclosed.
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; magnesium iron
hydroxy carbonate or hydrotalcite for pharmaceutical or
veterinary purposes; pharmaceutical and veterinary
preparations for use in renal dialysis and in the treatment
of renal diseases and kidney ailments; phosphate binders for
pharmaceutical purposes for use in the treatment of
hyperphosphataemia.
Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical [ and veterinary ] preparations for the treatment of musculoskeletal, renal, endocrinal, and neurological diseases; Pharmaceutical preparations, namely, phosphate binders for use in the treatment of hyperphosphataemia; Magnesium iron hydroxy carbonate and hydrotalcite for medical, pharmaceutical [ and veterinary ] preparations for use in renal dialysis and in the treatment of renal diseases and kidney ailments; pharmaceutical [ and veterinary ] preparations for use in treating bone, muscle and kidney diseases and disorders; pharmaceutical [ and veterinary ] preparations for controlling phosphorous metabolism and calcium metabolism
86.
Stable cytochrome P450 24 (CYP24) expressing cell line and methods and uses thereof
The invention relates to a stable recombinant host cell comprising a CYP24 nucleic acid. The host cell is preferably a mammalian cell or an insect cell. The cell is useful for identifying modulators of CYP24 that can be used in the treatment of CYP24 expression-related medical conditions.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
This invention relates to a monoclonal antibody for CYP24 and to methods and uses therefore, such as in Western blot analysis, immunohistochemisty, protein purification; diagnostics, such as for cancer, vitamin D metabolic conditions and the like.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry; chemical products and reagents for use in biotechnology (other than for medical or veterinary use); biological preparations for use in biotechnology (other than medical). Pharmaceutical, sanitary and biotechnology (for medical use) preparations and substances; prescription pharmaceuticals, and biotechnology preparations and substances, for humans as well as other pharmaceutical, and biotechnology (for medical use), products in tablet and/or capsule form; biological preparations for use in biotechnology; chemical products and reagents for use in biotechnology (medical or veterinary use); injectable solutions for medical purposes; dietetic substances adapted for medical use; disinfectants; syrups for pharmaceutical purposes; vaccines; pre-filled syringes for medical use; parts and fittings for the aforesaid products. Surgical, medical, dental and veterinary apparatus and instruments; orthopaedic articles; suture materials; syringes for injections; disposable syringes; inhalers and injectors for medical use; medical and dental syringes; parts and fittings for the aforesaid products. Medical, hygienic and beauty care services; scientific and industrial research relating to pharmaceuticals and biotechnology; health information services, namely, providing information on products and services; the provision of information on pharmaceutical and biotechnology services.
